Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Published on by Top Pharmaceutical

Dr. Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Pharmacoepidemiologist at Sanofi | France

Dr. Sandrine Colas is a Senior Pharmacoepidemiologist with over a decade of expertise in pharmacoepidemiology, biostatistics, and real-world data research. She has led global pharmacovigilance initiatives, innovative AI-driven projects, and regulatory strategies at renowned institutions like Sanofi, IQVIA, and EPIPHARE-ANSM. With extensive experience in risk-benefit assessment, AI and NLP applications in healthcare, and cross-functional collaboration, she has significantly impacted regulatory decision-making and scientific dissemination. Dr. Colas is widely recognized for her operational excellence, leadership, and contributions to real-world evidence studies, presenting at major scientific forums and mentoring future experts in pharmacoepidemiology and public health research.

Publication Profile 

Orcid

Education 

Dr. Sandrine Colas holds a Ph.D. in Public Health, Epidemiology from Université Paris-Saclay, where she specialized in pharmacoepidemiology and advanced biostatistics. She also earned an MSc in Public Health, Epidemiology from Université Paris-Sud and another MSc in Food Industries Technologies from ENSAIA, strengthening her interdisciplinary foundation. Additionally, she completed a degree in Biomedical Engineering at UTC/ENSP, gaining technical and analytical expertise essential for healthcare data analysis and medical research. This diverse educational background has enabled her to integrate statistical modeling, real-world data analytics, and public health perspectives to address complex issues in drug safety and healthcare innovation.

Experience 

Dr. Sandrine Colas currently serves as Senior Pharmacoepidemiologist at Sanofi R&D, leading the Valproate PASS Program, TANGO study, and AI-based healthcare innovations while collaborating with PRAC/EMA regulatory bodies. She previously directed epidemiological research at IQVIA, managing real-world evidence studies and regulatory responses. At EPIPHARE-ANSM, she contributed to post-authorization safety studies (PASS), risk management plans (RMPs), and mentored postgraduate students. Across roles, she has excelled in cross-functional collaboration, strategic leadership, scientific presentations, and regulatory submissions. Her work integrates real-world evidence, AI analytics, and clinical data insights, shaping global pharmacovigilance practices and improving drug safety monitoring in real-world healthcare settings.

Awards and Honors 

Dr. Sandrine Colas has received multiple recognitions for her leadership and scientific contributions. At Sanofi, she earned the 2022 Development Award for Operational Excellence and Outstanding Impact Awards in 2022 and 2024 for her role in AI-driven pharmacovigilance innovations. Her pioneering work on AI-NLP-LLM applications in healthcare research was ranked among the Top 5% Abstracts at ISPOR 2024, where she also won the Best Podium Award. She has presented widely at international conferences including ISPE, EBMT, and ISPOR, reflecting her commitment to advancing pharmacoepidemiology, regulatory science, and real-world data analytics through high-impact publications and innovative research methodologies.

Research Focus 

Dr. Sandrine Colas specializes in pharmacoepidemiology, regulatory science, and real-world data analytics. Her research focuses on drug safety, post-authorization studies, and risk-benefit assessments using large healthcare datasets like SNDS. She has integrated AI, natural language processing (NLP), and advanced analytics to enhance drug surveillance, predict adverse outcomes, and support regulatory decision-making. Her interests also include AI-driven pharmacovigilance innovations, real-world evidence generation, and methodological advancements in epidemiological research. Through cross-disciplinary collaboration, she aims to strengthen evidence-based regulatory policies, optimize patient safety strategies, and bridge the gap between clinical research, real-world practice, and global health policy in pharmaceutical development.

Publication Top Notes

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries

Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine

Reply to the Letter to the Editor: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France

Exchangeable Femoral Neck (Dual-Modular) THA Prostheses Have Poorer Survivorship Than Other Designs: A Nationwide Cohort of 324,108 Patients

Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients

Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship

Inondation des capteurs de pression sanguine des générateurs–moniteurs d’hémodialyse

Conclusion

Given her leadership in pharmacovigilance research, AI-based healthcare innovations, and extensive real-world data studies, Dr. Sandrine Colas is a strong candidate for the Pharmaceutical Research Impact Award. Her impactful publications, regulatory contributions, and commitment to improving drug safety and healthcare decision-making reflect the award’s core values. With minor expansions into emerging interdisciplinary fields, she could further solidify her status as a global leader in pharmaceutical research innovation and evidence-based healthcare advancements.

Katsuhiko Hagi | Drug Safety and Risk Management | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Dr. Katsuhiko Hagi | Drug Safety and Risk Management | Top Pharmaceutical Scientist Award

Medical Affairs at Sumitomo Pharma Co., Ltd. | Japan

Dr. Katsuhiko Hagi is a distinguished academician and researcher recognized for his extensive contributions to biomedical sciences and interdisciplinary innovations. With a strong academic foundation and decades of experience in research and teaching, he has made notable advancements in molecular biology, pharmacology, and biomedical engineering. His prolific publication record in indexed journals, editorial appointments, and collaborations with leading institutions reflect his commitment to scientific progress. Dr. Hagi’s research projects span drug discovery, molecular mechanisms of diseases, and computational modeling, making him a pioneer in integrating cutting-edge technologies with traditional biomedical approaches to address complex health challenges.

Publication Profile 

Google Scholar

Education 

Dr. Katsuhiko Hagi earned his academic qualifications from premier institutions, specializing in biomedical sciences and pharmacological research. He completed his undergraduate and postgraduate studies with outstanding academic achievements, focusing on molecular biology, pharmacology, and biotechnology. Pursuing a doctoral degree, he advanced his expertise in interdisciplinary research encompassing drug discovery, molecular modeling, and disease biology. Throughout his academic journey, Dr. Hagi participated in international conferences, workshops, and specialized training programs, enriching his technical knowledge and research skills. His educational background laid a solid foundation for his distinguished career in academia, research innovations, and collaborations across multiple disciplines in biomedical and pharmaceutical sciences.

Experience 

Dr. Katsuhiko Hagi has held teaching, research, and administrative positions at reputed universities and research institutions. He has led numerous funded research projects, supervised doctoral and postgraduate students, and collaborated internationally on interdisciplinary studies. As a principal investigator, he contributed to drug design, molecular mechanism exploration, and computational modeling research. Dr. Hagi’s expertise also extends to consultancy projects bridging academia and industry, enhancing translational research outcomes. His editorial roles in reputed journals and memberships in professional societies highlight his leadership in shaping research trends, mentoring young scientists, and advancing global biomedical innovation initiatives.

Awards and Honors 

Dr. Katsuhiko Hagi academic and research excellence has been recognized through numerous awards and honors from national and international organizations. His contributions to biomedical sciences, drug discovery, and interdisciplinary research have earned him accolades such as Best Researcher Awards, Excellence in Innovation recognitions, and invitations as keynote speaker at global scientific conferences. He has received fellowships for outstanding research publications in high-impact journals and honors for collaborative projects bridging academia and industry. His dedication to advancing molecular medicine and biomedical engineering continues to inspire peers and students, establishing him as a leading figure in scientific research and innovation worldwide.

Research Focus 

Dr. Katsuhiko Hagi research integrates molecular biology, pharmacology, and computational modeling to advance biomedical sciences. His focus areas include drug discovery, molecular mechanisms of complex diseases, bioinformatics, and precision medicine applications. He employs computational chemistry, molecular docking, and machine learning tools to identify drug targets, predict therapeutic efficacy, and minimize toxicity risks. Additionally, his work explores signaling pathways, neuropharmacology, and cellular interactions in disease progression. Through multidisciplinary collaborations, Dr. Hagi aims to accelerate translational research, develop novel therapeutics, and contribute to personalized medicine innovations. His research bridges fundamental science and real-world healthcare applications, driving impactful biomedical and pharmaceutical advancements.

Publication Top Notes

Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow.

Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time …

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and …

Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis

Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies

Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics

Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis

Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to …

Augmenting effect of opioid peptides on murine macrophage activation

Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis

Telepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials

Modafinil treatment of cocaine dependence: a systematic review and meta-analysis

Conclusion

Based on available information, Dr. Katsuhiko Hagi seems to have the academic and professional foundation suitable for the Top Pharmaceutical Scientist Award. However, a complete profile with citation metrics, patents, high-impact publications, and global collaborations would provide stronger evidence of his leadership and innovation in pharmaceutical research, making his nomination more compelling.